

Continuous glucose monitors	and supplies- Medicare
Policy Number:	M20221212131
Effective Date:	1/1/2023
Sponsoring Department:	Pharmacy
Impacted Department(s):	N/A
Type of Policy: ☐ Internal        Ex	xternal
<b>Data Classification:</b> □Confident	ial ⊠Restricted □Public
Applies to (Line of Business):	
<ul><li>□ Corporate (All)</li><li>□ State Products, if yes which plan</li><li>Plus; □Essential Plan</li></ul>	ı(s): □MediSource; □MediSource Connect; □Child Health
oxtimes Medicare, if yes, which plan(s): $oxtimes$	MAPD; □PDP; ⊠ISNP; ⊠CSNP
☐ Commercial, if yes, which type:	□ Large Group; □ Small Group; □ Individual
	cific Summary Plan Descriptions (SPDs) to determine any pre- ents and coverage limitations. In the event of any conflict between this ne SPD shall supersede the policy.)
Excluded Products within the	e Selected Lines of Business (LOB)
N/A	
Applicable to Vendors? Yes	$\square$ No $\boxtimes$
Purpose and Applicability:	
To provide Independent Health membe	ers with consistent access to therapeutic and non-therapeutic

continuous glucose monitors and supplies as medically necessary for patients with diabetes. Prior

authorization is required to assure safe, effective use of this diabetic supply.

Continuous glucose monitors and supplies- Medicare



Prior authorization applies to members who are newly prescribed a therapeutic or non-therapeutic continuous glucose monitor as part of their diabetes treatment plan (new starts).

### **Policy:**

Coverage for Continuous Glucose Monitoring Systems and supplies may be obtained from an in-network Durable Medical Equipment (DME) provider or Retail Pharmacy.

Coverage is provided for non-therapeutic and therapeutic continuous glucose monitors and supplies. Coverage for therapeutic continuous glucose monitors and supplies is limited to preferred products. FreeStyle Libre, Freestyle Libre 2, Freestyle Libre 3, Dexcom G6, and Dexcom G7 are Independent Health's preferred therapeutic continuous glucose monitors.

Continuous glucose monitors and supplies are available at network retail pharmacies without prior authorization for members using insulin to control their diabetes. A prescription goes through online if the patient's Independent Health prescription history documents concurrent or prior (within the previous 108 days) use of insulin.

**Freestyle Libre, Freestyle Libre 2, and Freestyle Libre 3:** Members are allowed to fill 2 sensors for a 28-day supply, up to 6 sensors for an 84-day supply. Members are allowed to fill one receiver per year.

**Dexcom G6 and Dexcom G7:** Members are allowed to fill 3 sensors for a 30-day supply, up to 9 sensors for a 90-day supply. Member may also fill 1 wireless transmitter every 90 days. Members may fill one receiver device every 1 year. (Dexcom G7 sensors include a built-in transmitter)

The prescriber can request authorization using the standard authorization process if the Independent Heath prescription history does not document concurrent use of insulin and for members who are obtaining their continuous glucose monitors and supplies from a durable medical equipment (DME) provider. The Pharmacy Services Department may authorize coverage of Continuous Glucose Monitors and supplies when the following criteria are met:

- Member has a diagnosis of diabetes; and
- Member is using insulin or
- Member has a history of problematic hypoglycemia with documentation of at least one of the following:
  - Recurrent (more than one) level 2 hypoglycemic events (glucose <54mg/dL (3.0mmol/L))
    that persist despite multiple (more than one) attempts to adjust medication(s) and/or
    modify the diabetes treatment plan; or</li>
  - A history of one level 3 hypoglycemic event (glucose <54mg/dL (3.0mmol/L))
     characterized by altered mental and/or physical state requiring third-party assistance
     for treatment of hypoglycemia</li>



<b>Duration of Approval:</b>	Duration	of	<b>Approva</b>	l:
------------------------------	----------	----	----------------	----

If criteria for authorization are met, approval may be provided indefinitely.

The Office of the Medical Director is responsible for all adverse determinations. Denied authorization requests can be appealed through the Complaint and Appeals process.

**Pre-Authorization Required?** Yes ⊠ No□

#### **Definitions**

- A therapeutic (or non-adjunctive) CGM can be used as a replacement for fingerstick blood glucose testing for diabetes treatment decisions.
- A non-therapeutic (or adjunctive) CGM cannot be used to make insulin-dosing decisions and is used in conjunction with finger stick testing with a standard, home glucose monitor.
- E2102 ADJUNCTIVE CONTINUOUS GLUCOSE MONITOR OR RECEIVER
- E2103 NON-ADJUNCTIVE, NON-IMPLANTED CONTINUOUS GLUCOSE MONITOR OR RECEIVER
- A4238 SUPPLY ALLOWANCE FOR ADJUNCTIVE CONTINUOUS GLUCOSE MONITOR (CGM), INCLUDES ALL SUPPLIES AND ACCESSORIES, 1 MONTH SUPPLY = 1 UNIT OF SERVICE
- A4239 SUPPLY ALLOWANCE FOR NON-ADJUNCTIVE, NON-IMPLANTED CONTINUOUS GLUCOSE MONITOR (CGM), INCLUDES ALL SUPPLIES AND ACCESSORIES, 1 MONTH SUPPLY = 1 UNIT OF SERVICE

#### References

**Related Policies, Processes and Other Documents** 

**Non-Regulatory references** 



## **Regulatory References**

Centers for Medicare and Medicaid Services (CMS) Local Coverage Determination (LCD) Document L33822 Glucose Monitors. https://www.cms.gov/medicare-coverage-database/search.aspx

# **Version Control**

Signature / Approval on File? Yes ⊠ No□

Revision Date	Owner	Notes
7/1/2023	Pharmacy	Revised-L33822 revised 4.16.2023
11/16/2023	Pharmacy	Reviewed
11/21/2024	Pharmacy	Reviewed
12/18/2024	Pharmacy	UM Committee Review only